HC Wainwright Cuts BioNTech (NASDAQ:BNTX) Price Target to $130.00

BioNTech (NASDAQ:BNTX) had its target price reduced by equities researchers at HC Wainwright from $140.00 to $130.00 in a report issued on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price objective indicates a potential upside of 52.49% from the company’s previous close.

BNTX has been the topic of several other research reports. Leerink Partners lowered shares of BioNTech from an “outperform” rating to a “market perform” rating and set a $113.00 target price on the stock. in a report on Monday, February 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of BioNTech in a research note on Friday, January 9th. Morgan Stanley cut their price target on shares of BioNTech from $134.00 to $125.00 and set an “overweight” rating for the company in a research report on Tuesday, March 10th. Jefferies Financial Group reaffirmed a “buy” rating on shares of BioNTech in a research note on Wednesday, March 25th. Finally, BMO Capital Markets decreased their price objective on BioNTech from $143.00 to $128.00 and set an “outperform” rating on the stock in a report on Wednesday, March 11th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $133.07.

BioNTech Trading Down 0.5%

BNTX stock opened at $85.25 on Tuesday. The company has a market capitalization of $21.43 billion, a PE ratio of -16.27 and a beta of 1.51. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.49 and a current ratio of 7.54. BioNTech has a one year low of $79.52 and a one year high of $124.00. The company’s 50 day moving average price is $103.23 and its two-hundred day moving average price is $101.47.

Institutional Investors Weigh In On BioNTech

Several institutional investors have recently added to or reduced their stakes in BNTX. Larson Financial Group LLC increased its position in shares of BioNTech by 86.4% in the fourth quarter. Larson Financial Group LLC now owns 274 shares of the company’s stock valued at $26,000 after acquiring an additional 127 shares during the period. EFG International AG bought a new stake in shares of BioNTech in the fourth quarter worth about $29,000. Caitong International Asset Management Co. Ltd increased its holdings in BioNTech by 520.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company’s stock valued at $30,000 after purchasing an additional 260 shares during the period. Financial Consulate Inc. bought a new position in BioNTech during the 3rd quarter valued at approximately $36,000. Finally, Huntington National Bank lifted its holdings in BioNTech by 1,266.7% in the 3rd quarter. Huntington National Bank now owns 410 shares of the company’s stock worth $40,000 after buying an additional 380 shares during the period. Hedge funds and other institutional investors own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.